Results-Significant proteinuria (> 0.15 g/24 h) was found in 31 (82%) of the 38 patients in the streptokinase group (mean 0-47 g124 h (95% confidence interval 0-35 to 0-6 gd24 h)) in the 24 hours after admission compared with six (27%) out of 22 in the non-streptokinase group (mean 0-17 g/24 h (0.12 to 0-2 g124 h); P = 0.008). In the streptokinase group this decreased to the normal range by day 3 (mean 0-15 g124 h (0 1 to 0-22 g/24 h); P = 0 0001 v baseline). Electrophoresis of urine showed the proteinuria to be glomerular in origin. Creatinine clearance and serum creatinine and urea concentrations were similar in both groups. In the streptokinase group detectable streptokinase IgG titres were found in 28 out of 32 (87%) patients. The median titre on admission was 16 (range 0-110); it felil to 3 (range 0-80; P = 0-001) by day 2 and increased to 61 (range 0-7700; P = 0-0002 v baseline) by day 7. Conclusions-Streptokinase was associated with significant early onset proteinuria of glomerular origin. This started to resolve by day 3 and resulted in no deterioration in overall renal finction. The temporal relation to the initial fall in antibody titre suggests that it could be the result of immune complex deposition in the glomeruli. (Br Heart_ 1995;74:354-357) specific antibodies against streptokinase,7 but, no relation has been found between the more frequent minor reactions-for example, hypotension and rigors-and streptokinase antibodies.8 Proteinuria may be a subclinical response to streptokinase that could be related to circulating specific antibody present at the time of treatment.
tion. Setting-Tertiary referral centre and city general hospital. Patients-60 consecutive patients with acute myocardial infarction. Thirty eight were given streptokinase and 17 tissue plasminogen activator (alteplase) and five no thrombolytic agent (non-streptokinase group). Main outcome measures-Proteinuria and creatinine clearance on admission (day 1) and on days 3 and 6; serum urea and creatinine concentrations on days 1 and 7; streptokinase IgG on days 1, 2, and 7.
Results-Significant proteinuria (> 0.15 g/24 h) was found in 31 (82%) of the 38 patients in the streptokinase group (mean 0-47 g124 h (95% confidence interval 0-35 to 0-6 gd24 h)) in the 24 hours after admission compared with six (27%) out of 22 in the non-streptokinase group (mean 0-17 g/24 h (0.12 to 0-2 g124 h); P = 0.008). In the streptokinase group this decreased to the normal range by day 3 (mean 0-15 g124 h (0 1 to 0-22 g/24 h); P = 0 0001 v baseline). Electrophoresis of urine showed the proteinuria to be glomerular in origin. Creatinine clearance and serum creatinine and urea concentrations were similar in both groups. In the streptokinase group detectable streptokinase IgG titres were found in 28 out of 32 (87%) patients. The median titre on admission was 16 (range 0-110); it felil to 3 (range 0-80; P = 0-001) by day 2 and increased to 61 (range 0-7700; P = 0-0002 v baseline) by day 7. Conclusions-Streptokinase was associated with significant early onset proteinuria of glomerular origin. This started to resolve by day 3 and resulted in no deterioration in overall renal finction. The temporal relation to the initial fall in antibody titre suggests that it could be the result of immune complex deposition in the glomeruli. No patient in either group developed macroscopic haematuria. Thirty one patients in the streptokinase group (82%) had proteinuria greater than the normal range (> 0 15 g/24 h) in the initial 24 hours after admission (mean 0 47 g/24 h (95% confidence interval 0 35 to 0-6 g/24 h)) compared with six (27%) in the non-streptokinase group (mean 0 17 g/24 h (0.12 to 0.2 g/24 h; P = 0-008)) (figure 1). By day 3 the mean value in the streptokinase group had decreased to 0 15 g/24 h (0 1 to 0'22 g/24 h; P = 0 0001) and was 0-15 g/24 h (0-13 to 0-22 g/l h) by day 6 (P < 0'0001 v baseline). In the non-streptokinase group proteinuria was unchanged during the three time periods studied (day 3, mean 0 11 g/24 h (0-08 to 0 14 g/24 h); day 6, mean 0 14 g/24 h (0 1 to 0 18 g/24 h)). The electrophoretic pattern of the proteinuria in the streptokinase group was similar in all patients. The predominant protein was albumin (confirmed by densitometry and immunonephelometry), with numerous additional higher and lower molecular weight proteins (figure 2), indicating glomerular proteinuria. In the non-streptokinase group both the frequency and range of proteinuria (0-049-0-32 g/24 h) in the first 24 hours were less than in the streptokinase treated group (range 0-048-1-5 g/24 h). Creatinine clearance and serum urea and creatinine concentrations were similar in both groups and remained unchanged throughout the study (table) .
Of those treated with streptokinase, 32 patients had serum samples for assessment of streptokinase IgG. Detectable antibody titres were found in 28 patients (87%). The median IgG titre on admission was 16 (range 0-110); it had decreased to 3 (0-80) by day 2 and increased to 61 (0-7700; P = 0-0002 v baseline) by day 7, indicating the beginning of the secondary immunoglobulin response.6 The median streptokinase IgG titre in the nonstreptokinase group at presentation was 52-5 (0-3500) and was unchanged on day 7 (table). Although the titres in this group were unchanged, they were higher than in the streptokinase group on days 1 and 2 (day 1, P = 0 0 16; day 2, P = 0 0008) but were similar There was no correlation between the degree of proteinuria in the initial 24 hour period and the serum streptokinase IgG titre at presentation in the streptokinase group (r = 0 09; P = 0-6) or with the fall in titre from day I to day 2 (r = 016; P= 0-4). No correlation was found between baseline proteinuria and peak creatine kinase activity in either group (streptokinase, r = 0 1; P = 04; n8; non-streptokinase, ro=0P1, P = 09) or between baseline proteinuria and the area under the creatine kinase time-activity curve (streptokinase, r = 0-16, P = 0 4; nonstreptokinase., r = 0-1; P = 0 07). There was also no correlation between proteinuria and peak plasma creatine kinase MB activity or area under the time-activity curve for this enzyme. The degree of proteinuria did not relate to the frequency of left ventricular failure or reinfarction complicating acute myocardial infarction in either group.
Discussion
Significant proteinuria was found in a substantial proportion (82%) of patients treated with streptokinase but in only 27% of those not receiving streptokinase. Among those in the non-streptokinase group the range of proteinuria was also less than in the streptokinase group. The proteinuria was a temporary phenomenon and started to improve by day 3, though it was not completely resolved in all patients by day 6. A longer follow up period would be necessary to ensure resolution.
Some patients, however, may have had a degree of renal impairment before infarction, but data were not available to confirm this. The proteinuria was not associated with a deterioration in renal function as determined by changes in creatinine clearance or serum urea or creatinine concentration. Acute myocardial infarction may be complicated by factors that can cause poor renal perfusion (left ventricular failure, arrhythmias, etc), but both groups of patients were similar in age, size of infarct, and prevalence of complications of acute myocardial infarction.
The groups differed in the site of infarction and in the prevalence of previous myocardial infarction. The predominance of inferior infarction in the streptokinase group can be explained by the results of a recent major trial in which streptokinase was recommended in the management of inferior infarction and tissue plasminogen activator in anterior infarction.1' The higher incidence of previous myocardial infarction in the non-streptokinase group can be explained by the frequent avoidance of repeat treatment with streptokinase. This may also explain the higher streptokinase IgG titres found in the non-streptokinase group, which remained unchanged throughout the period of the study. The high titres reflect the development of a secondary immunoglobulin response to the previously administered streptokinase. The extent of myocardial infarction and its complications were similar in both groups, and the excess of proteinuria in the streptokinase group could not be explained on the basis of acute myocardial infarction and its complications or by any differences between the two groups. Proteinuria can also be associated with an acute phase response, which is well documented in acute myocardial infarction,'2 but, the onset and resolution of the proteinuria were more rapid and the degree of proteinuria greater than would be usual in an acute phase response. The small protein load contained in a bolus dose of streptokinase would be unlikely to cause proteinuria as a result of protein load.'3 Seven patients in the non-streptokinase group had proteinuria in excess of the normal range, that resolved over the next six days (overall results were not significant). Proteinuria had not completely resolved in all patients and again may indicate previous renal impairment (no data available) or renal impairment after infarction, though not associated with changes in creatinine clearance or serum creatinine concentration. Gosling et al showed microalbuminuria in patients with acute myocardial infarction,' and this would account for the mild proteinuria (< 0-32 g/24 h) in the non-streptokinase group but not the excess of proteinuria in the other group.
The occurrence of proteinuria in the streptokinase group coincided with the fall in antibody titre from day 1 to day 2. Firstly, the fall in titre could be explained by immune complex formation, as 87% of patients had detectable specific circulating streptokinase IgG before they were given streptokinase. Circulating IgG containing immune complexes have been shown immediately after treatment with streptokinase.'4 These immune complexes may deposit in the glomeruli before being removed, and this could result in proteinuria. This would account for the glomerular proteinuria found in those treated with streptokinase and not observed in those not receiving streptokinase. The degree of proteinuria was not related to antibody titre at presentation, although most patients had low titres at presentation (median 16).
Secondly, antibody mediated activities, including immune complex formation, are more importantly determined by antibody affinity than by antibody concentration."5 The resolution of the proteinuria probably follows removal of the immune complexes by phagocytosis.
Although we found no relation of antibody titre to proteinuria, antibody titres were generally low. Further studies would be necessary to evaluate (a) whether patients with high antibody titres, such as patients previously treated with streptokinase or those who had had a recent streptococcal infection, would be at risk of developing greater degrees of proteinuria and (b) whether patients with pre-existing renal disease might be at risk of deterioration in renal function after administration of streptokinase.
We conclude that streptokinase treatment in patients with acute myocardial infarction is commonly associated with transient proteinuria in excess of that expected with an acute vascular event. The proteinuria was starting to resolve by day 3 and was not associated with a deterioration in renal function. The onset of proteinuria coincides with the fall in streptokinase IgG, suggesting that deposition of glomerular immune complex could account for this phenomenon.
